Janssen’s Tremfya maintains three years of remission in Phase II Crohn’s disease trial

Janssen Pharmaceuticals has announced that its Tremfya (guselkumab) demonstrated improving rates of clinical remission and endoscopic response maintained across the three-year Phase II Crohn’s disease study.